104 related articles for article (PubMed ID: 36964000)
1. Serologic responses to COVID-19 vaccination in children with history of multisystem inflammatory syndrome (MIS-C).
Perez MA; Hsiao HM; Chen X; Kunkel A; Baida N; Hussaini L; Lu AT; Kao CM; Laham FR; Hunstad DA; Beltran Y; Hammett TA; Godfred-Cato S; Chahroudi A; Anderson EJ; Belay E; Rostad CA
Vaccine; 2023 Apr; 41(17):2743-2748. PubMed ID: 36964000
[TBL] [Abstract][Full Text] [Related]
2. Functional Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Variants in Children With Coronavirus Disease 2019, Multisystem Inflammatory Syndrome in Children, and After Two Doses of BNT162b2 Vaccination.
Rostad CA; Chen X; Sun HY; Hussaini L; Lu A; Perez MA; Hsiao HM; Anderson LJ; Anderson EJ
J Infect Dis; 2022 Sep; 226(7):1237-1242. PubMed ID: 35639597
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 mRNA BNT162b2 vaccine immunogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS).
Ludwikowska KM; Popiel A; Matkowska-Kocjan A; Biela M; Wójcik M; Szenborn F; Wielgos K; Pielka-Markiewicz E; Zaryczański J; Kursa MB; Szenborn L
Vaccine; 2023 May; 41(21):3317-3327. PubMed ID: 37087396
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infection triggers more potent antibody-dependent cellular cytotoxicity (ADCC) responses than mRNA-, vector-, and inactivated virus-based COVID-19 vaccines.
Zedan HT; Smatti MK; Al-Sadeq DW; Al Khatib HA; Nicolai E; Pieri M; Bernardini S; Hssain AA; Taleb S; Qotba H; Issa K; Abu Raddad LJ; Althani AA; Nasrallah GK; Yassine HM
J Med Virol; 2024 Mar; 96(3):e29527. PubMed ID: 38511514
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children.
Bellusci L; Grubbs G; Sait S; Yonker LM; Randolph AG; Novak T; Kobayashi T; ; Khurana S
Nat Commun; 2023 Dec; 14(1):7952. PubMed ID: 38040697
[TBL] [Abstract][Full Text] [Related]
6. COVID-19 vaccine induced poor neutralization titers for SARS-CoV-2 omicron variants in maternal and cord blood.
Govindaraj S; Cheedarla N; Cheedarla S; Irby LS; Neish AS; Roback JD; Smith AK; Velu V
Front Immunol; 2023; 14():1211558. PubMed ID: 37465682
[TBL] [Abstract][Full Text] [Related]
7. Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses against the SARS-CoV-2 Omicron Variant in Adolescents and Adults.
Gupta SL; Mantus G; Manning KE; Ellis M; Patel M; Ciric CR; Lu A; Turner JS; O'Halloran JA; Presti RM; Joshi DJ; Ellebedy AH; Anderson EJ; Rostad CA; Suthar MS; Wrammert J
J Virol; 2022 Sep; 96(17):e0058222. PubMed ID: 35976000
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects.
Haveri A; Solastie A; Ekström N; Österlund P; Nohynek H; Nieminen T; Palmu AA; Melin M
Eur J Immunol; 2022 May; 52(5):816-824. PubMed ID: 35312186
[TBL] [Abstract][Full Text] [Related]
9. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Adenoviral Vector Vaccination Elicits a Robust Memory B Cell Response with the Capacity to Recognize Omicron BA.2 and BA.5 Variants.
Fryer HA; Hartley GE; Edwards ESJ; Varese N; Boo I; Bornheimer SJ; Hogarth PM; Drummer HE; O'Hehir RE; van Zelm MC
J Clin Immunol; 2023 Oct; 43(7):1506-1518. PubMed ID: 37322095
[TBL] [Abstract][Full Text] [Related]
11. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection.
Lapp SA; Edara VV; Lu A; Lai L; Hussaini L; Chahroudi A; Anderson LJ; Suthar MS; Anderson EJ; Rostad CA
PLoS One; 2021; 16(8):e0256482. PubMed ID: 34449792
[TBL] [Abstract][Full Text] [Related]
12. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination.
Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A
Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
15. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.
Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM
Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252
[TBL] [Abstract][Full Text] [Related]
16. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
17. Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort.
Lavender B; Hooker C; Frampton C; Williams M; Carson S; Paterson A; McGregor R; Moreland NJ; Gell K; Priddy FH; Wiig K; Le Gros G; Ussher JE; Brewerton M
Vaccine; 2023 Aug; 41(38):5535-5544. PubMed ID: 37516574
[TBL] [Abstract][Full Text] [Related]
18. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera.
Muik A; Lui BG; Wallisch AK; Bacher M; Mühl J; Reinholz J; Ozhelvaci O; Beckmann N; Güimil Garcia RC; Poran A; Shpyro S; Finlayson A; Cai H; Yang Q; Swanson KA; Türeci Ö; Şahin U
Science; 2022 Feb; 375(6581):678-680. PubMed ID: 35040667
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
[TBL] [Abstract][Full Text] [Related]
20. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]